Search

Willow bark

Nemolizumab

[A264254] By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

Probucol

A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

Ferumoxytol

high dose by rapid intravenous injection [L2181]. … In January of 2015, the EMA withdrew marketing authorisation for Rienso (ferumoxytol) due to safety concerns.

Tisotumab vedotin

Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells.

Pancuronium

As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

Cystine

A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

Galantamine

[A182993] The drug was approved by the FDA in 2001 for the treatment of mild to moderate dementia of the Alzheimer's type. … [L13571] It is therefore not considered to be a disease-modifying drug.

Alfuzosin

[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.

Thiopental

It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. … Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)